$0.20
(Market cap
$19,704 Mln
Revenue (TTM)
$14,563 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
2.8 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-11.3 %
-
Industry P/E
26.75
-
EV/EBITDA
13
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
1,164,552,654
10 Years Aggregate
CFO
$21,281.60 Mln
EBITDA
$17,210.40 Mln
Net Profit
$3,516.60 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Viatris (VTRS)
| 39.5 | 29.0 | 10.0 | 98.1 | 23.2 | 2.0 | -7.7 |
|
BSE Sensex*
| -11.0 | -1.9 | -8.7 | -7.1 | 6.7 | 9.1 | 11.5 |
|
S&P 100
| 7.3 | 11.2 | 10.1 | 31.0 | 25.0 | 15.0 | 15.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Viatris (VTRS)
| 0.0 | 14.8 | -2.7 | -17.7 | -27.8 | -6.8 | -26.6 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Viatris (VTRS)
|
17.4 | 19,704.2 | 14,562.6 | -296.5 | -1.5 | -2 | -- | 1.4 |
| 208.5 | 3,58,270.2 | 62,819.0 | 3,639.0 | 11.3 | -- | 99.4 | 50.5 | |
| 336.5 | 1,77,978.6 | 37,238.0 | 7,800.0 | 29.1 | 82.9 | 22.9 | 19.5 | |
| 56.4 | 1,13,682.1 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 15.7 | 5.7 | |
| 1,015.8 | 8,62,305.0 | 72,249.5 | 25,275.0 | 43.6 | 91.9 | 34.3 | 27.1 | |
| 133.1 | 1,65,774.4 | 29,734.0 | 9,216.0 | 30.0 | 40.9 | 18.2 | 6.9 | |
| 230.4 | 5,33,030.0 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 25.6 | 6.6 | |
| 113.5 | 2,74,842.1 | 65,593.0 | 8,935.0 | 30.5 | 18.3 | 31.3 | 6.0 | |
| 149.7 | 2,77,112.2 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 20.8 | 7.2 | |
| 26.0 | 1,47,102.7 | 63,315.0 | 7,491.0 | 17.0 | 8.1 | 19.7 | 1.6 |
Shareholding Pattern
View DetailsAbout Viatris (VTRS)
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments:... Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Address: Robert J. Coury Global Center, Canonsburg, PA, United States, 15317 Read more
-
CEO & Director
Mr. Scott Andrew Smith
-
CEO & Director
Mr. Scott Andrew Smith Ph.D.
-
Headquarters
Canonsburg, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Viatris (VTRS)
What is the current share price of Viatris Inc (VTRS) Today?
The share price of Viatris Inc (VTRS) is $17.37 (NASDAQ) as of 13-May-2026 16:13 EDT. Viatris Inc (VTRS) has given a return of 23.24% in the last 3 years.
What is the current PB & PE ratio of Viatris Inc (VTRS)?
Since, TTM earnings of Viatris Inc (VTRS) is negative, P/E ratio is not available.
The P/B ratio of Viatris Inc (VTRS) is 1.37 times as on 12-May-2026, a 76 discount to its peers’ median range of 5.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.15
|
0.99
|
|
2024
|
-23.42
|
0.80
|
|
2023
|
238.97
|
0.64
|
|
2022
|
6.52
|
0.64
|
|
2021
|
-12.89
|
0.80
|
What is the 52 Week High and Low of Viatris Inc (VTRS)?
The 52-week high and low of Viatris Inc (VTRS) are Rs 17.53 and Rs 8.19 as of 14-May-2026.
What is the market cap of Viatris Inc (VTRS)?
Viatris Inc (VTRS) has a market capitalisation of $ 19,704 Mln as on 12-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Viatris Inc (VTRS)?
Before investing in Viatris Inc (VTRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.